Literature DB >> 22409266

Assessing education in pulmonary rehabilitation: the Understanding COPD (UCOPD) questionnaire.

Brenda O'Neill1, Denise Cosgrove, Joseph MacMahon, Evie McCrum-Gardner, Judy M Bradley.   

Abstract

There is currently no questionnaire available that comprehensively assesses patients' understanding, self-efficacy and satisfaction with the education component of pulmonary rehabilitation. The aim of this study was to develop the Understanding COPD (UCOPD) questionnaire. The key stages in the development of the UCOPD questionnaire were: (i) Generation of questions, and assessment of face and content validity, user-centredness, acceptability and feasibility; (ii) Assessment of plain English and readability; (iii) Assessment of structural validity; (iv) Assessment of test-retest reliability and internal consistency; (v) Assessment of the responsiveness, convergent validity and floor and ceiling effects. The UCOPD questionnaire assesses understanding, self-efficacy and use of key self-management skills (Section A) and satisfaction (Section B). It has good validity and practical properties, and readability was acceptable. It has good test-retest reliability (Section A: ICC range: 0.87 to 0.96; Section B: Wilcoxon: p > 0.05) and internal consistency (Cronbach's Alpha range: 0.78 to 0.95). It is responsive to pulmonary rehabilitation (Mean change: About COPD: 18.26 [12.12 to 24.40]%, Managing Symptoms 20.94 [13.86 to 28.01]%, Accessing Help and Support 24.06 [14.53 to 33.60]%, Total 20.59 [14.43 to 26.75]%, p < 0.001). It had a moderate correlation with the Bristol COPD Knowledge Questionnaire (BCKQ): pre-pulmonary rehabilitation: r = 0.41, p = 0.02; post-pulmonary rehabilitation: r = 0.35, p = 0.047. In conclusion, the UCOPD questionnaire offers the opportunity to assess the benefit of the education component of pulmonary rehabilitation in terms of its effect on understanding, self-efficacy and satisfaction. Further research is needed across different pulmonary rehabilitation settings to demonstrate the robustness of the UCOPD questionnaire, and to establish the minimum clinically important difference.

Entities:  

Mesh:

Year:  2012        PMID: 22409266     DOI: 10.3109/15412555.2011.644601

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  6 in total

1.  Knowledge gaps in patients with COPD and their proxies.

Authors:  Nienke Nakken; Daisy J A Janssen; Esther H A van den Bogaart; Jean W M Muris; Jan H Vercoulen; Frank L Custers; Gerben P Bootsma; Michiel H M Gronenschild; Emiel F M Wouters; Martijn A Spruit
Journal:  BMC Pulm Med       Date:  2017-10-30       Impact factor: 3.317

2.  Translation, cross-cultural adaptation, and reliability of the Understanding COPD questionnaire for use in Brazil.

Authors:  Anamaria Fleig Mayer; Aline Almeida Gulart; Karoliny Dos Santos; Katerine Cristhine Cani; Manuela Karloh; Brenda O'Neill
Journal:  J Bras Pneumol       Date:  2018 Jul-Aug       Impact factor: 2.624

3.  Using self-determination theory to predict self-management and HRQoL in moderate-to-severe COPD.

Authors:  Liam Knox; Gareth Norris; Keir Lewis; Rachel Rahman
Journal:  Health Psychol Behav Med       Date:  2021-06-06

4.  Facilitating education in pulmonary rehabilitation using the living well with COPD programme for pulmonary rehabilitation: a process evaluation.

Authors:  Denise Cosgrove; Joseph Macmahon; Jean Bourbeau; Judy M Bradley; Brenda O'Neill
Journal:  BMC Pulm Med       Date:  2013-08-05       Impact factor: 3.317

5.  Correlates of disease-specific knowledge in Chinese patients with COPD.

Authors:  Carlos Kh Wong; W C Yu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-14

6.  Improving acceptance and uptake of pulmonary rehabilitation after acute exacerbation of COPD: Acceptability, feasibility, and safety of a PR "taster" session delivered before hospital discharge.

Authors:  Siobhan Camille Milner; Jean Bourbeau; Sara Ahmed; Tania Janaudis-Ferreira
Journal:  Chron Respir Dis       Date:  2019 Jan-Dec       Impact factor: 2.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.